<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thrombolysis is increasingly being used in treating <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> but it is also accompanied with a serious complication of <z:hpo ids='HP_0001342'>cerebral hemorrhage</z:hpo> in a dose-dependent fashion </plain></SENT>
<SENT sid="1" pm="."><plain>As a lower dose may result in decreased effectiveness, we tested the efficacy of combining a neuroprotective agent, topiramate (TPM), with lower doses of intra-arterial urokinase in an embolic <z:hpo ids='HP_0001297'>stroke</z:hpo> model </plain></SENT>
<SENT sid="2" pm="."><plain>Focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> was produced by introduction of an autogenous <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> into the right middle cerebral artery </plain></SENT>
<SENT sid="3" pm="."><plain>Urokinase was infused via the ipsilateral internal carotid artery and neuroprotective agent, TPM, was administrated intra-peritoneally 2 h following ischemic insult </plain></SENT>
<SENT sid="4" pm="."><plain>The animals were assigned to five groups: (1) control group (n=6); (2) urokinase 5000 units/kg (n=8); (3) urokinase at 2500 units/kg (n=8); (4) topiramate at 20 mg/kg (n=8); (5) urokinase at 2500 units/kg and topiramate at 20 mg/kg (n=8) </plain></SENT>
<SENT sid="5" pm="."><plain>Neurobehavioral outcome and the degree of brain <z:mpath ids='MPATH_124'>infarct</z:mpath> volume were assessed at 24 h </plain></SENT>
<SENT sid="6" pm="."><plain>Three animals in the group treated by high dose urokinase developed <z:hpo ids='HP_0002170'>intracranial hemorrhage</z:hpo> but none in other groups </plain></SENT>
<SENT sid="7" pm="."><plain>Animals in <z:hpo ids='HP_0000001'>all</z:hpo> medication-groups showed significant improvement in neurobehavioral score </plain></SENT>
<SENT sid="8" pm="."><plain>Post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> treatment with urokinase or TPM alone significantly attenuated brain <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (low-dose urokinase, 39.1+/-13.0%, p&lt;0.05; high-dose, 18.4+/-8.5%, p&lt;0.001; TPM, 20 </plain></SENT>
<SENT sid="9" pm="."><plain>1+/-11.2%, p&lt;0.001) when compared to the control (54.2+/-9.04%) </plain></SENT>
<SENT sid="10" pm="."><plain>Addition of TPM to low dose urokinase achieved better neuroprotection (8.2+/-6.0%) than any single-drug-treated groups </plain></SENT>
<SENT sid="11" pm="."><plain>Our data suggests that combination of low dose urokinase with a neuroprotective agent may benefit <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> treatment by improving neurologic recovery, attenuating infarction size, and reducing the risk of <z:hpo ids='HP_0001342'>cerebral hemorrhage</z:hpo> </plain></SENT>
</text></document>